Fishing Martha's 

Vineyard 

with 

Captain Chris Peters

Today that it all has submitted a study protocol to the U announced.

He is Chairman, Department of Hematology at Lahey Clinic and Oncology Professor of Medicine, Tufts University College of Medication. Tufts University will take part as the study's U.S. Clinical site. The process submission is backed by solid, positive data from Can-Fite's Phase I/II HCC research published in The Oncologist, and presented at the 18th Globe Congress on Developments in Oncology. The Phase I/II research data demonstrated that the trial goals were effectively achieved. CF102 had a very favorable security profile with very encouraging median overall survival and one individual who has been treated for 4 years with CF102.About the Clinical Advancement System for Skyla The authorization of Skyla is backed by data from a Stage 3 trial of 2,884 women aged 18-35. There have been 1,432 females who received Skyla, which 39 % hadn’t yet had a kid. The analysis was a multicenter, multi-national randomized open-label research carried out in 11 countries in European countries, Latin America, the U.S. And Canada. The Pearl Index was the principal efficacy endpoint utilized to assess contraceptive dependability.